Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × Thalidomide × Clear all

Phase

Status

Completed 9 Withdrawn 1

Sponsor Class

OTHER 2 NETWORK 2 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Paclitaxel 28 Cisplatin 26 Cyclophosphamide 25 Carboplatin 24 Bevacizumab 22 Nivolumab 19 pembrolizumab 18 Docetaxel 18 Rituximab 17 Fluorouracil 17 Dexamethasone 15 avelumab 14 Gemcitabine 14 Leucovorin 13 Ipilimumab 11 Capecitabine 11 fludarabine 10 atezolizumab 10 130-nm albumin-bound paclitaxel 10 venetoclax 9 Radiotherapy 9 Cetuximab 9 ALT-803 9 Pemetrexed 8 trametinib 7 Radiosurgery 7 Prednisone 7 Oxaliplatin 7 Lenalidomide 7 Bendamustine Hydrochloride 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03608501 2020-01-14

IDEALL

Takeda

Phase 2 Withdrawn

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡